A PHASE I TRIAL OF TARGETED IMMUNOTHERAPY WITH DARATUMUMAB FOLLOWING MYELOABLATIVE TOTAL BODY IRRADIATION (TBI)-BASED CONDITIONING AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATON IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH HIGH-RISK T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA (T- ALL/T-LLy) (ALLO-T-DART) (IND 159396): A PTCTC FACILITATED STUDY. (October 2022)

• Record Type: Journal Article
• Authors: Quigg, T.; Flower, A.; Teachey, D.; Lim, M.; Chu, Y.; Harrison, L.; Morris, E.; Gardenswartz, A.; Hochberg, J.; Ozkaynak, M.; Rosenblum, J.; Milner, J.; Pehlivan, K.; Levendoglu-Tugal, O.; Fabricatore, S.; Wolownik, K.; Ayello, J.; Rigot, O.; Klejmont, L.; Campbell, M.; Gonzalez, I.; Otero, N.; Budhram, A.; Mintzer, E.; Mahanti, H.; Dufresne, J.; Liu, D.; Ahmed, T.; Steinberg, A.; Sweeney, R.; McHale, P.; Islam, H.; Gerard, P.; Moorthy, C.; Voss, S.; Miles, R.; Audino, A.; Mo, X.; Stanek, J.; Olshen, A.; Hermiston, M.; Seif, A.; Cairo, M.;
• Is Part Of: Leukemia research. Volume 121(2022)Supplement
• Page Start: S71
• Page End: S73
• Publication Date: 2022-10
• Subjects: Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/S0145-2126(22)00315-0
• Languages: English
• ISSNs: 0145-2126